Affymetrix Inc. (AFFX) and TessArae LLC said the Food and Drug Administration has granted emergency use authorization for a H1N1 influenza detection panel.
Shares rose 9.6% premarket to $6.08. The stock has nearly doubled this year.
The product was created by privately held TessArae using technology from Affymetrix, which makes products to help analyze genetic information.
TessArae's product isn't the only one to receive such emergency clearance from the FDA for H1N1 detection, but the company said one of its product's unique aspects is that it "directly generates genomic sequence from multiple influenza virus genes" to identify the particular H1N1 virus strain in a single test.
-By Kevin Kingsbury; Dow Jones Newswires; 212-416-2354; email@example.com